ThanikachalamKKhanG. Colorectal cancer and nutrition. Nutrients2019; 11(1): 164.
2.
TsoiKKFHiraiHWChanFCH, et al.Predicted increases in incidence of colorectal cancer in developed and developing regions, in association with ageing populations. Clin Gastroenterol Hepatol2017; 15(6): 892–900.e4.
3.
HallerDGTaberneroJMarounJ, et al.Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol2011; 29(11): 1465–1471.
4.
SuiXChenRWangZ, et al.Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis2013; 4(10): e838.
5.
ChenWZhengRBaadePD, et al.Cancer statistics in China, 2015. CA Cancer J Clin2016; 66(2): 115–132.
6.
PalmaSZwengerAOCroceMV, et al.From molecular biology to clinical trials: toward personalized colorectal cancer therapy. Clin Colorectal Cancer2016; 15(2): 104–115.
7.
WooISJungYH. Metronomic chemotherapy in metastatic colorectal cancer. Cancer Lett2017; 400: 319–324.
8.
BregoliLMoviaDGavigan-ImedioJD, et al.Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomedicine2016; 12(1): 81–103.
9.
HeCTangZTianH, et al.Co-delivery of chemotherapeutics and proteins for synergistic therapy. Adv Drug Deliv Rev2016; 98: 64–76.
10.
XuZChanHMLiC, et al.Synthesis, structure, and cytotoxicity of oxaliplatin-based platinum(IV) anticancer prodrugs bearing one axial fluoride. Inorg Chem2018; 57(14): 8227–8235.
11.
OmarSLemonnierBJonesN, et al.Antimicrobial activity of extracts of eastern North American hardwood trees and relation to traditional medicine. J Ethnopharmacol2000; 73(1–2): 161–170.
12.
LuKPZhouXZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol2007; 8(11): 904–916.
13.
FilaCMetzCvan der SluijsP. Juglone inactivates cysteine-rich proteins required for progression through mitosis. J Biol Chem2008; 283(31): 21714–21724.
14.
NeriIBianchiFGiacominiF, et al.Acute irritant contact dermatitis due to Juglans regia. Contact Dermatitis2006; 55(1): 62–63.
15.
YehESMeansAR. PIN1, the cell cycle and cancer. Nat Rev Cancer2007; 7(5): 381–388.
16.
AithalBKSunil KumarMRRaoBN, et al.Evaluation of pharmacokinetic, biodistribution, pharmacodynamic, and toxicity profile of free juglone and its sterically stabilized liposomes. J Pharm Sci2011; 100(8): 3517–3528.
17.
RiddellIA. Cisplatin and oxaliplatin: our current understanding of their actions. Met Ions Life Sci, 182018: 18.
18.
HuC-MJZhangLAryalS, et al.Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A2011; 108(27): 10980–10985.
19.
AryalSHuC-MJFangRH, et al.Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release. Nanomedicine (Lond)2013; 8(8): 1271–1280.
20.
PiaoJ-GWangLGaoF, et al.Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano2014; 8(10): 10414–10425.
21.
GuoYWangDSongQ, et al.Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano2015; 9(7): 6918–6933.
22.
FangRHHuC-MJZhangL. Nanoparticles disguised as red blood cells to evade the immune system. Expert Opin Biol Ther2012; 12(4): 385–389.
23.
RaoLBuL-LXuJ-H, et al.Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance. Small2015; 11(46): 6225–6236.
24.
LukBTFangRHHuC-MJ, et al.Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theranostics2016; 6(7): 1004–1011.
25.
RaoLXuJ-HCaiB, et al.Synthetic nanoparticles camouflaged with biomimetic erythrocyte membranes for reduced reticuloendothelial system uptake. Nanotechnology2016; 27(8): 085106.
26.
LukBTHuCMFangRH, et al.Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale2014; 6(5): 2730–2737.
27.
BHATERIAMRACHUMALLURSINGHR, et al.Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies. Expert Opin Drug Delivery2014; 11(8): 1219–1236.
28.
ZARRINAFOROOZESHMHAMIDIM. Carrier erythrocytes: recent advances, present status, current trends and future horizons. Expert Opin Drug Delivery2014; 11(3): 433–447.
29.
UsmanWMPhamTCKwokYY, et al.Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun2018; 9(1): 2359–2366.
30.
FuXYangYLiX, et al.RGD peptide-conjugated selenium nanoparticles: antiangiogenesis by suppressing VEGF-VEGFR2-ERK/AKT pathway. Nanomedicine2016; 12(6): 1627–1639.
31.
TeesaluTSugaharaKNRuoslahtiE. Tumor-penetrating peptides. Front Oncol2013; 3: 216.
32.
SugaharaKNTeesaluTKarmaliPP, et al.Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science2010; 328(5981): 1031–1035.
33.
MaLChenQMaP, et al.iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery. Nanomedicine (Lond)2017; 12(16): 1991–2006.
34.
HanahanDWeinbergRA. The hallmarks of cancer. Cell2000; 100(1): 57–70.
35.
TeesaluTSugaharaKNKotamrajuVRRuoslahtiE,C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A2009; 106(38): 16157–16162.
36.
ParikhAAFanFLiuWB, et al.Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol2004; 164(6): 2139–2151.
37.
YuDCWabyJSChirakkalH, et al.Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation. Mol Cancer2010; 9: 276.
38.
KadonosonoTYamanoAGotoT, et al.Cell penetrating peptides improve tumor delivery of cargos through neuropilin-1-dependent extravasation. J Control Release2015; 201: 14–21.
39.
HaspelNZanuyDNussinovR, et al.Binding of a C-end rule peptide to the neuropilin-1 receptor: a molecular modeling approach. Biochemistry2011; 50(10): 1755–1762.
40.
DingNZouZShaH, et al.iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer. Nat Commun2019; 10(1): 1336.
41.
JayaAgnihotriNarendraKumar Jain. Biodegradable long circulating cellular carrier for antimalarial drug pyrimethamine. Artif Cells Nanomed Biotechnol2013; 41(5): 309–314.
42.
BhateriaMRachumalluRSinghR, et al.Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies. Expert Opin Drug Deliv2014; 11(8): 1219–1236.
43.
ZarrinAForoozeshMHamidiM. Carrier erythrocytes: recent advances, present status, current trends and future horizons. Expert Opin Drug Deliv2014; 11(3): 433–447.
44.
HuC-MJFangRHLukBT, et al.‘Marker-of-self’ functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale2013; 5(7): 2664–2668.
45.
GuptaNPatelBAhsanF. Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: preparation and characterization. Pharm Res2014; 31(6): 1553–1565.
46.
SugaharaKNTeesaluTKarmaliPP, et alTissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell2009; 16(6): 510–520.
47.
LiuXLinPPerrettI, et al.Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. J Clin Invest2017; 127(5): 2007–2018.
48.
WangYXieYLiJ, et al.Tumor-penetrating nanoparticles for enhanced anticancer activity of combined photodynamic and hypoxia-activated therapy. ACS Nano2017; 11(2): 2227–2238.
49.
LukBTZhangL. Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release2015; 220(Pt B): 600–607.
50.
WangPGaoCWangW, et al.Juglone induces apoptosis and autophagy via modulation of mitogen-activated protein kinase pathways in human hepatocellular carcinoma cells. Food Chem Toxicol2018; 116(Pt B): 40–50.
51.
XuMCheungCC-MChowC, et al.Overexpression of PIN1 enhances cancer growth and aggressiveness with cyclin D1 induction in EBV-associated nasopharyngeal carcinoma. PLoS One2016; 11(6): e0156833.
52.
LiaoWXiangWWangF-F, et al.Curcumin inhibited growth of human melanoma A375 cells via inciting oxidative stress. Biomed Pharmacother2017; 95: 1177–1186.
